Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
101 participants
INTERVENTIONAL
2007-12-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
50% of the consenting subjects will take part in the lottery and use the Med-eMonitor as a device to monitor adherence
Lottery arm (Lottery and Med-eMonitor)
Lottery and Med-eMonitor
2
50% of the consenting subjects will use only the Med-eMonitor as a device to monitor adherence
Non-Lottery (Med-eMonitor only)
Med-eMonitor only
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lottery arm (Lottery and Med-eMonitor)
Lottery and Med-eMonitor
Non-Lottery (Med-eMonitor only)
Med-eMonitor only
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* On warfarin managed at the AC clinic
* Target INR 2.0-3.0 or 2.5-3.5
* At maintenance phase of therapy (defined as stable INR with stable warfarin dosing over at least 2 consecutive visits)
Exclusion Criteria
* Unwillingness to participate or to sign a consent form(refusal)
* Inability to participate because of advances dementia, advanced Alzheimer's disease or other impairment affecting ability to provide informed consent and/or quality data or utilize the Med-eMonitor
* Participation in a current study that does not permit participation in another study
* End stage or terminal illness with anticipated life expectancy of 6 months or less
* INR over the upper limit for the individual's range at the time of enrollment (e.g.,\>3.0 or \>3.5, depending on the target range)
* Diagnosed with antiphospholipid antibody syndrome or abnormal INR prior to starting warfarin
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aetna, Inc.
INDUSTRY
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Pennsylvania School of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kevin G Volpp, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Pennsylvania
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital of the University of Pennsylvania Anticoagulation Management Center
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
806634
Identifier Type: -
Identifier Source: org_study_id